How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk Hits A 10-Year Low - I Think The Market Is Making A Mistake

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

Novo Nordisk: One Of The Most Mispriced Alphas In The Market

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Novo Nordisk: Alzheimer’s Failure Puts More Pressure on Oral Semaglutide Launch in Obesity

While disappointing, the failure of these trials was more likely than not, and we are not changing our fair value estimate.
24/7 Wall St.

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Why Is Everyone Talking About Novo Nordisk Stock?

Finally, the stock now looks reasonably valued, especially given significant clinical and commercial catalysts on the horizon ...

What’s Next for Novo Nordisk?

After [losing out to Pfizer]( ...

The new generation of weight-loss 'super jabs': They could help you lose up to a QUARTER of your body weight, keep you feeling fuller for longer - and they only ne…

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

The incredible NEW weight-loss 'super jabs': They burn weight fast, make you feel full for longer, only need to be injected once a month... and have less side-effects. Now ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...
Reuters

Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits

COPENHAGEN, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish ...
Morningstar

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial ...